Literature DB >> 15745778

Heterogeneity of the genetic risk in age-related macular disease: a population-based familial risk study.

Jacqueline J M Assink1, Caroline C W Klaver, Jeanine J Houwing-Duistermaat, Roger C W Wolfs, Cornelia M van Duijn, Albert Hofman, Paulus T V M de Jong.   

Abstract

OBJECTIVE: To assess the extent of heterogeneity of the genetic risk of age-related macular disease (AMD) among families.
DESIGN: Case-controlled population-based familial aggregation study. PARTICIPANTS: Participants comprised 190 first-degree relatives of 65 case probands and 347 relatives of 100 control probands. All probands had been identified from the baseline phase of the Rotterdam Study in The Netherlands.
METHODS: A family score was computed for each family based on the presence and type of macular disease, the expected risk of disease, and the number, extent of kinship, and age of all family members. MAIN OUTCOME MEASURES: Presence and stage of AMD as diagnosed on fundus photographs, family score, and logistic regression coefficient.
RESULTS: The family score of case families showed a peak of approximately 0 with a skewed tail (14% of families) of higher than expected risks of disease toward a maximum of 2.9. The family score of control families centered on 0, apart from 1 outlier. The risk of AMD increased significantly with higher family scores (beta = 1.34; P<0.001).
CONCLUSIONS: The heterogeneity of genetic risk among AMD families is considerable, and the proportion of high-risk families is relatively small. The family score method is relevant for genetic counseling as well as for implementation in studies of genetic dissection of AMD.

Entities:  

Mesh:

Year:  2005        PMID: 15745778     DOI: 10.1016/j.ophtha.2004.10.035

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  7 in total

1.  Progression of geographic atrophy and genotype in age-related macular degeneration.

Authors:  Michael L Klein; Frederick L Ferris; Peter J Francis; Anne S Lindblad; Emily Y Chew; Sara C Hamon; Jurg Ott
Journal:  Ophthalmology       Date:  2010-04-09       Impact factor: 12.079

2.  Risk factors for age-related maculopathy.

Authors:  Paul P Connell; Pearse A Keane; Evelyn C O'Neill; Rasha W Altaie; Edward Loane; Kumari Neelam; John M Nolan; Stephen Beatty
Journal:  J Ophthalmol       Date:  2009-09-06       Impact factor: 1.909

3.  Influence of CFH, HTRA1 and ARMS2 polymorphisms in the response to intravitreal ranibizumab treatment for wet age-related macular degeneration in a Spanish population.

Authors:  Fernando Cruz-Gonzalez; Lucia Cabrillo-Estevez; Vanesa Rivero-Gutierrez; Ana Sanchez-Jara; Lourdes De Juan-Marcos; Rogelio Gonzalez-Sarmiento
Journal:  Int J Ophthalmol       Date:  2016-09-18       Impact factor: 1.779

Review 4.  An update on the genetics of age-related macular degeneration.

Authors:  Hendrik P N Scholl; Monika Fleckenstein; Peter Charbel Issa; Claudia Keilhauer; Frank G Holz; Bernhard H F Weber
Journal:  Mol Vis       Date:  2007-02-07       Impact factor: 2.367

5.  The Rotterdam Study: objectives and design update.

Authors:  Albert Hofman; Monique M B Breteler; Cornelia M van Duijn; Gabriel P Krestin; Huibert A Pols; Bruno H Ch Stricker; Henning Tiemeier; André G Uitterlinden; Johannes R Vingerling; Jacqueline C M Witteman
Journal:  Eur J Epidemiol       Date:  2007-10-23       Impact factor: 8.082

6.  Using current data to define new approach in age related macular degeneration: need to accelerate translational research.

Authors:  Akshay Anand; Kaushal Sharma; Wei Chen; Neel Kamal Sharma
Journal:  Curr Genomics       Date:  2014-08       Impact factor: 2.236

7.  The Rotterdam Study: 2010 objectives and design update.

Authors:  Albert Hofman; Monique M B Breteler; Cornelia M van Duijn; Harry L A Janssen; Gabriel P Krestin; Ernst J Kuipers; Bruno H Ch Stricker; Henning Tiemeier; André G Uitterlinden; Johannes R Vingerling; Jacqueline C M Witteman
Journal:  Eur J Epidemiol       Date:  2009       Impact factor: 8.082

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.